Search Results - Raed Al-Rajabi

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma by Weijing Sun, Nirmal Veeramachaneni, Raed Al‐Rajabi, Rashna Madan, Anup Kasi, Mazin Al‐Kasspooles, Joaquina Baranda, Anwaar Saeed, Milind A. Phadnis, Andrew K. Godwin, Mojtaba Olyaee, Natalie Streeter, Alykhan Nagji, Junqiang Dai, Stephen Williamson

Get full text

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients by Ian M. Freed, Anup Kasi, Oluwadamilola Fateru, Mengjia Hu, Phasin Gonzalez, Nyla Weatherington, Harsh Pathak, Stephen Hyter, Weijing Sun, Raed Al-Rajabi, Joaquina Baranda, Mateusz L. Hupert, Prabhakar Chalise, Andrew K. Godwin, Malgorzata A. Witek, Steven A. Soper

Get full text

Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort by Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Baranda, Weijing Sun, Stephen Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Rashna Madan, Hassan Abushukair, Kelly Mulvaney, Andrew K. Godwin, Azhar Saeed

Get full text

Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma by Ghassan K. Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, Sarina A. Piha-Paul, Joseph S. Light, Scott Sherrin, Amin Yaqubie, Alison Clemens O’Neill, James J. Harding, Raed Al-Rajabi, Crystal S. Denlinger, Pablo Cano, Albert S. Cornelius, Eileen M. O'Reilly, Daniel DiPrimeo, Lisa D. Eli, John D. Gordan, David B. Solit

Get full text